FB23‐2 significantly affects the proliferation, differentiation, and apoptosis of human acute myeloid leukemia cells in vitro and in vivo.[156] These results suggest that small‐molecule inhibitors specifically targeting FTO could be developed for fighting against obesity‐related metabolic disorders and other events (Figure 5). This evidence concerns the gene FTO and obesity due to melanocortin 4 receptor deficiency.